Welcome to our dedicated page for ASSEMBLY BIOSCIENCES SEC filings (Ticker: ASMB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Assembly Biosciences, Inc. filings document a clinical-stage antiviral developer with common stock listed on the Nasdaq Global Select Market under ASMB. Recent 8-K reports furnish operating results and pipeline updates tied to investigational programs for recurrent genital herpes, chronic hepatitis delta virus and chronic hepatitis B virus, including disclosures on ABI-5366, ABI-1179, ABI-6250 and ABI-4334.
The filing record also covers the company’s collaboration revenue with Gilead, material definitive agreements, registered equity and warrant offerings, and securities registered under Section 12(b). Proxy and compensation-related filings describe governance, executive compensation, equity awards and performance-based cash bonus arrangements.
Gilead Sciences filed an amended ownership report showing a larger stake in Assembly Biosciences. Gilead now beneficially owns 4,977,089 shares of Assembly common stock, representing 25.1% of the outstanding shares based on 19,816,995 shares outstanding after the company’s most recent public offering.
On May 26, 2026, Gilead bought 471,698 Assembly shares in an underwritten public offering for total consideration of approximately $12,499,997, funded from its cash resources. Gilead also holds warrants covering 2,475,420 additional shares, but a 19.99% Beneficial Ownership Limitation means those underlying shares are not currently counted as beneficially owned.
Assembly Biosciences, Inc. completed an underwritten public offering of common stock and pre-funded warrants, generating approximately $107.4 million in net proceeds after underwriting discounts, commissions and estimated expenses. Gross proceeds were about $115.0 million, providing significant additional funding for the company’s biotechnology programs.
The deal included 3,358,602 common shares at $26.50 per share, pre-funded warrants to purchase up to 415,000 shares at $26.499 per warrant, and 566,040 additional shares purchased in full by the underwriters via a 30-day option. Executive officers and directors agreed to 90-day lock-up arrangements, and the company plans to use the proceeds mainly to fund clinical development of its pipeline candidates and for general corporate purposes.
Assembly Biosciences is offering 3,358,602 shares of common stock and pre-funded warrants to purchase up to 415,000 shares. The prospectus supplement sets an offering price of $26.50 per share (pre-funded warrants priced at $26.499), with estimated net proceeds of approximately $93.3 million (before expenses).
Proceeds are planned to fund clinical development of pipeline candidates and for general corporate purposes. The company reported 15,892,353 shares outstanding as of March 31, 2026. The underwriters have a 30-day option to purchase up to 566,040 additional shares.
Assembly Biosciences, Inc. is offering shares of its common stock and/or pre-funded warrants to purchase shares of common stock pursuant to a preliminary prospectus supplement dated May 21, 2026, subject to completion. The pre-funded warrants are exercisable for one share at an exercise price of $0.001 per share.
The company notes an indicated (non‑binding) interest from Gilead Sciences, Inc. to purchase up to a pro rata number of shares. Shares outstanding were 15,892,353 as of March 31, 2026; net tangible book value was approximately $198.6 million (about $12.50 per share) as of that date. The offering proceeds are intended to fund clinical development and for general corporate purposes.
Assembly Biosciences is expanding development of its investigational oral drug ABI-6250 beyond chronic hepatitis delta virus into primary biliary cholangitis and primary sclerosing cholangitis, two autoimmune cholestatic liver diseases with significant unmet medical need, particularly PSC where no therapies are approved.
ABI-6250 is a small-molecule inhibitor of the NTCP receptor on liver cells, blocking bile acid uptake and HDV entry. The company has completed a Phase 1a trial in healthy participants, showing target engagement and dose-dependent increases in plasma bile acids, and completed chronic toxicology studies supporting longer-term dosing.
The company plans a Phase 2 study of ABI-6250 in HDV in the fourth quarter of 2026 and a Phase 2 basket study in cholestatic liver diseases focused on PBC and PSC in the first quarter of 2027, following a pre-IND discussion with the U.S. Food and Drug Administration.
Assembly Biosciences, Inc. Schedule 13G reports that Paradigm-related reporting persons and Senai Asefaw directly beneficially own specified common stock positions as of the close of business on May 4, 2026.
The filing lists 865,251 shares (representing 5.4%) held by Paradigm BioCapital Advisors LP, Paradigm BioCapital Advisors GP LLC and Senai Asefaw, M.D., and 758,963 shares (representing 4.8%) held by Paradigm BioCapital International Fund Ltd. The filing cites 15,892,608 shares outstanding as of April 10, 2026 as the denominator for the percentage calculations.
Assembly Biosciences, Inc. reported a Q1 2026 net loss of $9.1M, slightly higher than the $8.8M loss a year earlier, as it continued investing in antiviral R&D. Collaboration revenue from Gilead was $8.2M, down from $9.4M, reflecting the timing of research services.
Total operating expenses were $19.6M, with research and development of $14.9M and general and administrative costs of $4.7M. Interest and other income rose to $2.3M due to a larger securities portfolio.
Cash, cash equivalents and marketable securities totaled $226.6M as of March 31, 2026, and management states this should fund operations into 2028. The company’s pipeline includes partnered genital herpes helicase‑primase inhibitors, HDV entry inhibitor ABI‑6250, capsid assembly modulator ABI‑4334 (now seeking partners) and NNPI candidate ABI‑7272.
Assembly Biosciences, Inc. reported first quarter 2026 results that show continued R&D investment alongside a manageable loss and solid cash position. Cash, cash equivalents and marketable securities totaled $226.6 million as of March 31, 2026, which the company believes can fund operations into 2028.
For the quarter, collaboration revenue from its Gilead partnership was $8.2 million, while research and development expenses were $14.9 million and general and administrative expenses were $4.7 million. Net loss attributable to common stockholders was $9.1 million, or $0.54 per share.
Operationally, the company completed Phase 1b studies for herpes candidates ABI-5366 and ABI-1179 and chronic toxicology studies for ABI-6250 in hepatitis delta virus. A Phase 2 study for ABI-6250 is expected to begin in the fourth quarter of 2026, and a decision on opting into a 40% U.S. cost-profit share with Gilead for the herpes program is planned by mid-2026.
Assembly Biosciences is asking stockholders to approve five key items at its 2026 annual meeting. The virtual-only meeting is scheduled for June 4, 2026 at 8:00 a.m. PDT. Holders of 15,892,608 shares of common stock as of April 10, 2026 may vote.
Stockholders will vote on electing nine directors, an advisory “say on pay” for named executive officers, and ratifying Ernst & Young LLP as auditor for 2026. They are also asked to approve increasing the 2018 Stock Incentive Plan share reserve by 1,200,000 shares and raising the Employee Stock Purchase Plan reserve to 515,000 shares. The Board recommends voting “FOR” all proposals and highlights a mainly independent Board, annual director elections, proxy access and the absence of a poison pill.